P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, The Journal of clinical investigation, vol.122, 2012.

M. H. Delfau-larue, High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01543670

M. Hartmann, Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling, Blood, vol.116, p.953, 2010.

B. Meissner, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, p.3161, 2013.

R. , Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma, Blood, vol.119, 1963.

J. Zhang, The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, p.2988, 2014.

R. , Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma, Nature medicine, vol.20, 2014.

S. Bea, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences of the United States of America, vol.110, p.18250, 2013.

A. Emadali, Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms, Blood, vol.127, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01920364

S. H. Swerdlow, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, p.2375, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

A. Clipson, KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype, Leukemia, vol.29, p.1177, 2015.

D. Chiron, Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer discovery, vol.4, p.1022, 2014.

M. A. Dawson, The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science, vol.355, p.1147, 2017.

P. Nagarajan, Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis, Oncogene, vol.28, p.1053, 2009.

D. Rodriguez, Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia, Blood, vol.126, p.195, 2015.

A. Pastore, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet. Oncology, vol.16, p.1111, 2015.

M. Busslinger, Transcriptional control of early B cell development, Annual review of immunology, vol.22, pp.55-79, 2004.

J. C. Byrd, R. R. Furman, S. E. Coutre, I. W. Flinn, J. A. Burger et al., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, The New England journal of medicine, vol.369, pp.32-42, 2013.

E. Campo and S. Rule, Mantle cell lymphoma: evolving management strategies, Blood, vol.125, pp.48-55, 2015.

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011.

R. Ceredig, A. G. Rolink, and G. Brown, Models of haematopoiesis: seeing the wood for the trees, Nature reviews Immunology, vol.9, pp.293-300, 2009.

C. Y. Cheah, J. F. Seymour, and M. L. Wang, Mantle Cell Lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, p.1256, 2016.

K. J. Cheung, D. E. Horsman, and R. D. Gascoyne, The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target, British journal of haematology, vol.146, pp.257-269, 2009.

D. Chiron, M. Di-liberto, P. Martin, X. Huang, J. Sharman et al., Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer discovery, vol.4, pp.1022-1035, 2014.

C. Cobaleda, A. Schebesta, A. Delogu, and M. Busslinger, Pax5: the guardian of B cell identity and function, Nature immunology, vol.8, pp.463-470, 2007.

R. P. Dekoter, H. J. Lee, and H. Singh, PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors, Immunity, vol.16, pp.297-309, 2002.

R. P. Dekoter and H. Singh, Regulation of B lymphocyte and macrophage development by graded expression of PU, Science, vol.1, pp.1439-1441, 2000.

R. Delarue, C. Haioun, V. Ribrag, P. Brice, A. Delmer et al., CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte, Blood, vol.121, pp.48-53, 2013.

M. Dreyling, W. Jurczak, M. Jerkeman, R. S. Silva, C. Rusconi et al., Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study, Lancet, vol.387, pp.770-778, 2016.

G. Fabbri, S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian et al., Analysis of the chronic lymphocytic leukemia coding, 2011.

K. Georgopoulos, Haematopoietic cell-fate decisions, chromatin regulation and ikaros, Nature reviews Immunology, vol.2, pp.162-174, 2002.

K. Georgopoulos, M. Bigby, J. H. Wang, A. Molnar, P. Wu et al.,

S. Gesk, W. Klapper, J. I. Martin-subero, I. Nagel, L. Harder et al., , vol.108, pp.1109-1110, 2006.

J. L. Gowans, The Role of Lymphocytes in the Destruction of Homografts, British medical bulletin, vol.21, pp.106-110, 1965.

A. Goy, R. Sinha, M. E. Williams, S. Kalayoglu-besisik, J. Drach et al., Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.31, pp.3688-3695, 2013.

S. Greenbaum and Y. Zhuang, , vol.99, pp.15030-15035, 2002.

T. C. Greiner, C. Dasgupta, V. V. Ho, D. D. Weisenburger, L. M. Smith et al., America, vol.103, pp.2352-2357, 2006.

P. S. Gudjonsson, E. Mariusdottir, H. B. Palsdottir, G. V. Einarsson, E. Jonsson et al., , 2012.

, Laeknabladid, vol.98, pp.585-589

O. Hagens, E. Minina, S. Schweiger, H. H. Ropers, and V. Kalscheuer, Characterization of FBX25, encoding a novel brain-expressed F-box protein, Biochimica et biophysica acta, vol.1760, pp.110-118, 2006.

J. Hagman, M. J. Gutch, H. Lin, and R. Grosschedl, EBF contains a novel zinc coordination motif and multiple dimerization and transcriptional activation domains, The EMBO journal, vol.14, pp.2907-2916, 1995.

A. M. Halldorsdottir, A. Lundin, F. Murray, L. Mansouri, S. Knuutila et al., Impact of TP53 mutation and 17p deletion in mantle cell lymphoma, Leukemia, vol.25, pp.1904-1908, 2011.

M. J. Henderson, M. A. Munoz, D. N. Saunders, J. L. Clancy, A. J. Russell et al., EDD mediates DNA damage-induced activation of CHK2, The Journal of biological chemistry, vol.281, pp.39990-40000, 2006.

J. Herglotz, L. Unrau, F. Hauschildt, M. Fischer, N. Kriebitzsch et al., Essential control of early B-cell development by Mef2 transcription factors, Blood, vol.127, pp.572-581, 2016.

A. Herrmann, E. Hoster, T. Zwingers, G. Brittinger, M. Engelhard et al., Improvement of overall survival in advanced stage mantle cell lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.27, pp.511-518, 2009.

G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump et al., , 2009.

B. Holkova, E. B. Perkins, V. Ramakrishnan, M. B. Tombes, E. Shrader et al., Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms, Clinical cancer research : an official journal of the American Association for Cancer Research, vol.17, pp.3388-3397, 2011.

R. Hromas, A. Orazi, R. S. Neiman, R. Maki, C. Van-beveran et al.,

, Hematopoietic lineage-and stage-restricted expression of the ETS oncogene family member PU.1, Blood, vol.82, pp.2998-3004

D. J. Inwards, P. A. Fishkin, D. W. Hillman, D. W. Brown, S. M. Ansell et al., , 2008.

A. Jaccard, N. Gachard, B. Marin, S. Rogez, M. Audrain et al., Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study, Blood, vol.117, pp.1834-1839, 2011.

P. Jares, D. Colomer, and E. Campo, Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics, Nature reviews Cancer, vol.7, pp.750-762, 2007.

P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, The Journal of clinical investigation, vol.122, pp.3416-3423, 2012.

D. F. Jelinek, R. C. Tschumper, G. A. Stolovitzky, S. J. Iturria, Y. Tu et al., Identification of a global gene expression signature of B-chronic lymphocytic leukemia, Molecular cancer research : MCR, vol.1, pp.346-361, 2003.

J. A. Jones, A. S. Rupert, M. Poi, M. A. Phelps, L. Andritsos et al., , 2001.

B. Meissner, R. Kridel, R. S. Lim, S. Rogic, K. Tse et al., The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, pp.3161-3164, 2013.

P. Meusers, M. Engelhard, H. Bartels, T. Binder, H. H. Fulle et al., , 1989.

B. Morgan, L. Sun, N. Avitahl, K. Andrikopoulos, T. Ikeda et al., Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation, The EMBO journal, vol.16, 1997.

R. D. Morin, M. Mendez-lago, A. J. Mungall, R. Goya, K. L. Mungall et al., Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, vol.476, pp.298-303, 2011.

C. G. Mullighan, S. Goorha, I. Radtke, C. B. Miller, E. Coustan-smith et al., , 2007.

M. A. Munoz, D. N. Saunders, M. J. Henderson, J. L. Clancy, A. J. Russell et al., The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints, Cell Cycle, vol.6, pp.3070-3077, 2007.

F. Fachetti, D. M. Jones, and T. Petrella, Annexe 1 : Classification internationale des maladies pour l'oncologie, troisième édition References 1, Classification of Tumours of Haematopoietic and Lymphoid Tissues

F. Lyon, , pp.145-147, 2008.

J. Feuillard, M. C. Jacob, and F. Valensi, Clinical and biologic features of CD4(1)CD56(1) malignancies, Blood, vol.99, issue.5, pp.1556-1563, 2002.

M. Ramanathan, J. Cerny, H. Yu, B. A. Woda, and R. Nath, A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm, Haematologica, vol.98, issue.3, p.36, 2013.

D. Roos-weil, S. Dietrich, and A. Boumendil,

, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, vol.121, issue.3, pp.440-446, 2013.

L. Chaperot, N. Bendriss, and O. Manches, Identification of a leukemic counterpart of the plasmacytoid dendritic cells, Blood, vol.97, issue.10, pp.3210-3217, 2001.

Y. Osaki, A. Yokohama, and A. Saito, Characterization of CD561 dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm?, PLoS One, vol.8, issue.11, p.81722, 2013.

T. Petrella, M. R. Comeau, and . Maynadiém, Agranular CD41 CD561 hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD561 precursor cells related to plasmacytoid monocytes, Am J Surg Pathol, vol.26, issue.7, pp.852-862, 2002.

F. Garnache-ottou, J. Feuillard, and C. Ferrand,

G. Goelams and . Study, Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia

, Br J Haematol, vol.145, issue.5, pp.624-636, 2009.

T. Marafioti, J. C. Paterson, and E. Ballabio, Novel markers of normal and neoplastic human plasmacytoid dendritic cells, Blood, vol.111, issue.7, pp.3778-3792, 2008.

F. Jardin, M. Callanan, and D. Penther, Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD41CD561 haematodermic neoplasms and contribute to the aggressiveness of the disease, Leukemia, vol.23, issue.4, pp.698-707, 2009.

D. Leroux, F. Mugneret, and M. Callanan, CD56(1) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique, Blood, vol.99, issue.1, pp.4154-4159, 2002.

K. Alayed, K. P. Patel, and S. Konoplev, TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow, Am J Hematol, vol.88, issue.12, pp.1055-1061, 2013.

F. Jardin, P. Ruminy, and F. Parmentier, TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm, Br J Haematol, vol.153, issue.3, pp.413-416, 2011.

J. Menezes, F. Acquadro, and M. Wiseman, Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm, Leukemia, vol.28, issue.4, pp.823-829, 2014.

R. Dijkman, R. Van-doorn, K. Szuhai, R. Willemze, M. H. Vermeer et al., Gene-expression profiling and array-based CGH classify CD41 CD561 hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities, Blood, vol.109, issue.4, pp.1720-1727, 2007.

M. R. Sapienza, F. Fuligni, and C. Agostinelli, AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies' and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition, Leukemia, vol.28, issue.8, pp.1606-1616, 2014.

A. Jerez, L. P. Gondek, and A. M. Jankowska, Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited, J Clin Oncol, vol.30, issue.12, pp.1343-1349, 2012.

D. Grimwade, H. Walker, and G. Harrison, Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial, Blood, vol.98, issue.5, pp.1312-1320, 2001.

J. C. Byrd, K. Mrózek, and R. K. Dodge, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B

, Blood, vol.100, issue.13, pp.4325-4336, 2002.

J. Krönke, E. C. Fink, and P. W. Hollenbach, Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS, Nature, vol.523, issue.7559, pp.183-188, 2015.

R. K. Schneider, V. Ademà, and D. Heckl, Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS, Cancer Cell, vol.26, issue.4, pp.509-520, 2014.

M. E. Varney, M. Niederkorn, and H. Konno, Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling, J Exp Med, vol.212, issue.11, pp.1967-1985, 2015.

L. Chaperot, A. Blum, and O. Manches, Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells, J Immunol, vol.176, issue.1, pp.248-255, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00286442

T. Maeda, K. Murata, and T. Fukushima, A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma, Int J Hematol, vol.81, issue.2, pp.148-154, 2005.

A. Fournier, A. Mcleer-florin, and C. Lefebvre, 1q12 Chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma, EMBO Mol Med, vol.2, issue.5, pp.159-171, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00482580

W. Mclaren, B. Pritchard, D. Rios, Y. Chen, P. Flicek et al., Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, vol.26, issue.16, pp.2069-2070, 2010.

T. Ernst, A. J. Chase, and J. Score, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nat Genet, vol.42, issue.8, pp.722-726, 2010.

V. Gelsi-boyer, V. Trouplin, and . Adélaï-d-ej, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, vol.145, issue.6, pp.788-800, 2009.

A. Emadali, S. Rousseaux, and J. Bruder-costa, Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers, EMBO Mol Med, vol.5, issue.8, pp.1180-1195, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00852222

J. P. Vert, N. Foveau, C. Lajaunie, and Y. Vandenbrouck, An accurate and interpretable model for siRNA efficacy prediction, BMC Bioinformatics, vol.7, p.520, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00433579

C. Lévy, C. Frecha, and C. Costa, Lentiviral vectors and transduction of human cancer B cells, Blood, vol.116, issue.3, pp.498-500, 2010.

A. Lajmanovich, J. B. Ribeyron, and A. Florin, Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell nonHodgkin's lymphoma, Exp Cell Res, vol.315, pp.3281-3293, 2009.

T. Bonnefoix and M. Callanan, Accurate hematopoietic stem cell frequency estimates by fitting multicell Poisson models substituting to the single-hit Poisson model in limiting dilution transplantation assays, Blood, vol.116, issue.14, pp.2472-2475, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00520297

Y. Hu and G. K. Smyth, ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays, J Immunol Methods, vol.347, issue.1-2, pp.70-78, 2009.

D. Grimwade, R. K. Hills, and A. V. Moorman, National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, vol.116, issue.3, pp.354-365, 2010.

N. C. Nicolaides, Z. Galata, T. Kino, G. P. Chrousos, and E. Charmandari, The human glucocorticoid receptor: molecular basis of biologic function, Steroids, vol.75, issue.1, pp.1-12, 2010.

C. G. Mullighan, L. A. Phillips, and X. Su, Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, Science, 2008.

L. Kuster, R. Grausenburger, and G. Fuka, ETV6/ RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling, Blood, vol.117, issue.9, pp.2658-2667, 2011.

L. Holmfeldt, L. Wei, and E. Diaz-flores, The genomic landscape of hypodiploid acute lymphoblastic leukemia, Nat Genet, vol.45, issue.3, pp.242-252, 2013.

S. Goossens, E. Radaelli, and O. Blanchet, ZEB2 drives immature T-cell lymphoblastic leukaemia online April 8, 2016.

I. Luquet, D. Penther, and C. Bastard,

E. Mecucci, D. Macintyre, E. Leroux, and . Brambilla,

M. Jacob and T. Bonnefoix,

I. Templier, T. Maeda, J. Bruder-costa, L. Chaperot, J. Plumas et al., Céline Suchaud-Martin

A. Emadali, N. Hoghoughi, S. Duley, and A. Hajmirza, Els Verhoeyen, Francois-Loic *Corresponding authors, S Rousseaux or S Khochbin, vol.823

E. Wang, L. Guarnieri, P. Wolgemuth, and D. J. , The testisspecific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids, sophie.rousseaux@ujf-grenoble.fr or Khochbin@ujf-grenoble.fr References Berkovits BD, vol.40, pp.7162-7175, 2012.

D. A. Bisgrove, T. Mahmoudi, P. Henklein, and E. Verdin, Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription, Proc Natl Acad Sci, vol.104, pp.13690-13695, 2007.

C. Cho, W. D. Willis, E. H. Goulding, H. Jung-ha, Y. C. Choi et al., Haploinsufficiency of protamine-1 or -2 causes infertility in mice, Nat Genet, vol.28, pp.82-86, 2001.

S. Dhar, A. Thota, and M. R. Rao, Insights into role of bromodomain, testis-specific (Brdt) in acetylated histone H4-dependent chromatin remodeling in mammalian spermiogenesis, J Biol Chem, vol.287, pp.6387-6405, 2012.

D. J. Dix, J. W. Allen, B. W. Collins, C. Mori, N. Nakamura et al., Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility, Proc Natl Acad Sci, vol.93, pp.3264-3268, 1996.

B. Florence and D. V. Faller, You bet-cha: a novel family of transcriptional regulators, Front Biosci, vol.6, pp.1008-1018, 2001.

B. A. Garcia, S. B. Hake, R. L. Diaz, M. Kauer, S. A. Morris et al., Organismal differences in post-translational modifications in histones H3 and H4, J Biol Chem, vol.282, pp.7641-7655, 2007.

J. Gaucher, N. Reynoird, E. Montellier, F. Boussouar, S. Rousseaux et al., From meiosis to postmeiotic events: the secrets of histone disappearance, FEBS J, vol.277, pp.599-604, 2010.

J. Govin, C. Caron, C. Lestrat, S. Rousseaux, and S. Khochbin, The role of histones in chromatin remodelling during mammalian spermiogenesis, Eur J Biochem, vol.271, pp.3459-3469, 2004.

J. Govin, J. Dorsey, J. Gaucher, S. Rousseaux, S. Khochbin et al., Systematic screen reveals new functional dynamics of histones H3 and H4 during gametogenesis, Genes Dev, vol.24, pp.1772-1786, 2010.

J. Govin, E. Escoffier, S. Rousseaux, L. Kuhn, M. Ferro et al., Pericentric heterochromatin reprogramming by new histone variants during mouse spermiogenesis, J Cell Biol, vol.176, pp.283-294, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00176730

J. Govin, C. Lestrat, C. Caron, C. Pivot-pajot, S. Rousseaux et al., Regulated hyperacetylation of core histones during mouse spermatogenesis: involvement of histone deacetylases, The Histone Code and Beyond, vol.79, pp.950-960, 2000.

R. Huang, M. A. Holbert, M. K. Tarrant, S. Curtet, D. R. Colquhoun et al., Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylation, J Am Chem Soc, vol.132, pp.9986-9987, 2010.

N. Kotaja, S. Kimmins, S. Brancorsini, D. Hentsch, J. L. Vonesch et al., Preparation, isolation and characterization of stage-specific spermatogenic cells for cellular and molecular analysis, Nat Methods, vol.1, pp.249-254, 2004.

D. Liu, M. M. Matzuk, W. K. Sung, Q. Guo, P. Wang et al., Cyclin A1 is required for meiosis in the male mouse, Nat Genet, vol.20, pp.377-380, 1998.

P. Liu, N. A. Jenkins, and N. G. Copeland, A highly efficient recombineering-based method for generating conditional knockout mutations, Genome Res, vol.13, pp.476-484, 2003.

M. M. Matzuk, M. R. Mckeown, P. Filippakopoulos, Q. Li, L. Ma et al., Small-molecule inhibition of BRDT for male contraception, Cell, vol.150, pp.673-684, 2012.

J. Moriniere, S. Rousseaux, U. Steuerwald, M. Soler-lopez, S. Curtet et al., Cooperative binding of two acetylation marks on a histone tail by a single bromodomain, Nature, vol.461, pp.664-668, 2009.
URL : https://hal.archives-ouvertes.fr/cea-00909643

M. Muller, P. Filippakopoulos, and S. Knapp, Bromodomains as therapeutic targets, Exp Rev Mol Med, vol.13, pp.1-21, 2011.

H. D. Nickerson, A. Joshi, and D. J. Wolgemuth, Cyclin A1-deficient mice lack histone H3 serine 10 phosphorylation and exhibit altered aurora B dynamics in late prophase of male meiosis, Dev Biol, vol.306, pp.725-735, 2007.

C. Pivot-pajot, C. Caron, J. Govin, A. Vion, S. Rousseaux et al., Acetylation-dependent chromatin reorganization by Brdt, a testis-specific bromodomain-containing protein, Mol Cell Biol, vol.23, pp.5354-5365, 2003.

S. Rousseaux, N. Reynoird, E. Escoffier, J. Thevenon, C. Caron et al., Epigenetic reprogramming of the male genome during gametogenesis and in the zygote, Reprod Biomed Online, vol.16, pp.492-503, 2008.

R. Sanchez and M. M. Zhou, The role of human bromodomains in chromatin biology and gene transcription, Curr Opin Drug Discov Dev, vol.12, pp.659-665, 2009.

K. Sasaki, T. Ito, N. Nishino, S. Khochbin, and M. Yoshida, Real-time imaging of histone H4 hyperacetylation in living cells, Proc Natl Acad Sci, vol.106, pp.16257-16262, 2009.

P. Sassone-corsi, Unique chromatin remodeling and transcriptional regulation in spermatogenesis, Science, vol.296, pp.2176-2178, 2002.

S. Schroder, S. Cho, L. Zeng, Q. Zhang, K. Kaehlcke et al., Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes, J Biol Chem, vol.287, pp.1090-1099, 2012.

E. Shang, H. D. Nickerson, D. Wen, X. Wang, and D. J. Wolgemuth, The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation, Development, vol.134, pp.3507-3515, 2007.

E. Shang, G. Salazar, T. E. Crowley, X. Wang, R. A. Lopez et al., Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Brd3, Brd4, and Brdt in the mouse testis, Gene Expr Patterns, vol.4, pp.513-519, 2004.

W. C. Skarnes, B. Rosen, A. P. West, M. Koutsourakis, W. Bushell et al., A conditional knockout resource for the genome-wide study of mouse gene function, Nature, vol.474, pp.337-342, 2011.

M. Tan, H. Luo, S. Lee, J. F. Yang, J. S. Montellier et al., Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification, Cell, vol.146, pp.1016-1028, 2011.

T. Ye, A. R. Krebs, M. A. Choukrallah, C. Keime, F. Plewniak et al., ) seqMINER: an integrated ChIP-Seq data interpretation platform, Nucleic Acids Res, vol.39, p.35, 2010.

K. Zhang, K. E. Williams, L. Huang, P. Yau, J. S. Siino et al., Histone acetylation and deacetylation: identification of acetylation and methylation sites of HeLa histone H4 by mass spectrometry, Mol Cell Proteomics, vol.1, pp.500-508, 2002.

R. Zhao, T. Nakamura, Y. Fu, Z. Lazar, and D. L. Spector, Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation, Nat Cell Biol, vol.13, pp.1295-1304, 2011.